iSpecimen® Founder and CEO Chris Ianelli to Co-Present at PMWC 2018 Silicon Valley

MOUNTAIN VIEW, Calif., Jan. 22, 2018 /PRNewswire/ -- iSpecimen Founder and CEO Christopher Ianelli, MD, PhD, will co-present on the value of human biospecimens in precision medicine discovery tomorrow (Tuesday, Jan. 23) at PMWC 2018 Silicon Valley.

The event, also known as the Personalized Medicine World Conference, covers technologies, initiatives, and clinical case studies that translate precision medicine into direct health care improvements. It runs runs Jan. 22-24 and is expected to draw 11,500 leaders, researchers, medical professionals, and innovators from healthcare and biotechnology. Visit iSpecimen in Booth #5.

Ianelli's session, called "Biospecimens as Building Blocks for Precision Medicine Discovery," will take place at 10:30 a.m. PST at the Computer History Museum in Mountain View, Calif.

The session will cover the role of annotated human biospecimens ? including tissue, biofluids and cells ? in precision medicine discovery and preclinical validation of hypotheses. Attendees will also learn how advances in technology are improving access to a diverse range of biospecimens from patient populations and yielding increasingly useful amounts of information upon analysis.

Ianelli's fellow panelists include:

• Renee Deehan-Kenney, PhD, Vice President, Computational Biology, Patients Like Me.
• Andrew Brooks, PhD, associate professor, director of the Bionomics Research and Technology Center (BRTC), Rutgers University.

About iSpecimen
Headquartered in Lexington, MA, iSpecimen is the marketplace for human biospecimens, providing researchers with the specimens they need from the patients they want. The privately held company has developed the iSpecimen Marketplace, an online platform connecting healthcare organizations that have access to patients and specimens with the scientists who need them. Proprietary, cloud-based technology enables researchers to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. Researchers easily and compliantly gain access to specimens to drive scientific discovery. Partner sites gain an opportunity to contribute to biomedical discovery as well as their bottom line. And ultimately, healthcare advances for all. For more information about iSpecimen, please visit www.ispecimen.com.

SOURCE iSpecimen